Lupin, a global pharmaceutical leader, is making strides in sustainable healthcare by developing respiratory inhalers with near-zero global warming potential (GWP). This move not only addresses environmental concerns but also ensures patients have access to effective and reliable treatments with minimal impact on the planet.
Global pharmaceutical giant Lupin is making waves in the fight against climate change with its commitment to developing respiratory inhalers using propellants with near-zero global warming potential. This initiative aligns with European regulations and reflects Lupin’s dedication to sustainable healthcare practices.
Merck unveils the Aptegra™ CHO genetic stability assay, a groundbreaking technology that revolutionizes biosafety testing in the pharmaceutical industry. By employing whole genome sequencing and bioinformatics, Aptegra™ accelerates biosafety evaluation, enabling faster delivery of new therapies to patients.
